INCYIncyte CorporationFinished
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
Endometrial Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 206 (final count)
- Started
- Jan 26, 2021
- Main results expected
- May 29, 2026
- Fully finished
- May 29, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Group A - Objective Response Rate
Measured over: up to 2.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04463771 · record last updated 2026-06-11 · checked 2026-11-09 15:47 UTC